Adalta Ltd
Price Chart
OHLC · volume · moving averages
Market Statistics
Today's trading range
Valuation
Fundamental multiples
Trading Activity
Volume & order book
Performance
Returns across timeframes
Technical Indicators
Momentum & moving averages
— From the desk
Latest News
AdAlta Partner to Provide Adapted CAR-T Mesothelioma Therapy in China under Special Access Scheme
AdAlta's EW-001 CAR-T gains China access under Lecheng scheme; BZDS1901 approved for mesothelioma at Ruijin Hospital, boosting ASX:1AD upside.
AdAlta inks major CAR-T deal for global development outside China
AdAlta (ASX:1AD) has secured exclusive rights to co-develop Shanghai Cell Therapy Group's BZDS1901 CAR-T therapy outside Greater China, a significant move validating its 'East-to-West' strategy and po
Market wrap: big banks send ASX into record territory
Australia’s big banks have pushed the ASX 200 to a record close of 7847 points after more signs of lower inflation in major economies caused a global relief rally. With interest rates now looking almost a certainty to fall in the big markets of the US, Europe and Australia, investors celebrated hard with a fresh […]
AdAlta’s AD-214 demonstrates safety and efficacy potential for fibrotic disease treatment
Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studies. The results are reported to have also positively answered key questions from pharmaceutical partner companies in support […]